Benzinga | Nov 9, 2020 08:10AM EST

Myriad Genetics Q1 Adj. EPS $(0.15) Beats $(0.30) Estimate, Sales $145.20M Down From $186.30M YoY

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.30) by 50 percent. This is a 287.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported $145.20 million in sales this quarter. This is a 22.06 percent decrease over sales of $186.30 million the same period last year.